TrialSignal
Clinical trial intelligence report
Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03504072-Jul 28, 2026
NCT ID
NCT03504072
Status
UNKNOWN
Phase
PHASE4
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Executive brief
Investment-Ready Snapshot
Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh is a PHASE4 clinical asset sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh in Spondyloarthritis. SEO and diligence focus: Tofacitinib 5 mg,, Etanercept, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03504072
Indication
Spondyloarthritis
Modality
small molecule
Target
Tofacitinib 5 mg,, Etanercept
Intervention
Tofacitinib 5 mg,, Etanercept
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.